Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?

References

• Eckard AR, McConsey GA. Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals. Curr HIV/AIDS Rep. 2014;11(3):263–270.
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection AIDS. 2007;21(5):617–623.
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006;42(7):1014–1020.
   PubMed Web of Science ®Google Scholar
• Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42(1):108–114.
   PubMed Web of Science ®Google Scholar
• Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19(3):402–409.
   PubMed Web of Science ®Google Scholar
• Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS. 2004;18(3):475–483.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Harris DR, Emmanuel P, et al. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: adolescent trials network study 021B. Clin Infect Dis. 2012;55(3):461–468.
   PubMed Web of Science ®Google Scholar
• Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV + postmenopausal women. Osteoporos Int. 2005;16(11):1345–1352.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165–2174.
   PubMed Web of Science ®Google Scholar
• Shiau S, Broun EC, Arpadi SM, et al. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS. 2013; 27(12):1949–1957.
   PubMed Web of Science ®Google Scholar
• Assoumou L, Katlama C, Viard JP, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27(15):2425–2430.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5):554–561.
   PubMed Web of Science ®Google Scholar
• Short CE, Shaw SG, Fisher MJ, et al. Prevalence of and risk factors for osteoporosis and fracture among a male HIV-infected population in the UK. Int J STD AIDS. 2014;25(2):113–121.
   PubMed Web of Science ®Google Scholar
• Hileman CO, Labbato DE, Storer NJ, et al. Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS. 2014; 28(12):1759–1767.
   PubMed Web of Science ®Google Scholar
• Kooij KW, Wit FW, Bisschop PH, et al. Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease. J Infect Dis. 2015;211(4):539–548.
   PubMed Web of Science ®Google Scholar
• Adeyemi OM, Agniel D, et al. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr. 2011;57(3):197–204.
   PubMed Web of Science ®Google Scholar
• Lambert AA, Drummond MB, et al. Risk factors for vitamin D deficiency among HIV-infected and uninfected injection drug users. PLoS ONE. 2014;9(4).
   Web of Science ®Google Scholar
• Grigsby IF, Pham L, Mansky LM, et al. Tenofovir-associated bone density loss. Ther Clin Risk Manag. 2010;6:41–47.
   PubMed Web of Science ®Google Scholar
• Childs KE, Fishman SL, Constable C, et al. Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS research and human retroviruses. 2010;26(8):855–859.
   PubMed Web of Science ®Google Scholar
• Havens PL, Kiser JJ, Stephensen CB, et al. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team. Antimicrob Agents Chemother. 2013;57(11):5619–5628.
   PubMed Web of Science ®Google Scholar
• Havens PL, Stephensen CB, Hazra R, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Clin Infect Dis. 2012;54(7):1013–1025.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther (Lond.). 2010;15(3):425–429.
   PubMed Web of Science ®Google Scholar
• Grant PM, Kitch D, McComsey GA, et al. Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals. J Infect Dis. 2016;214(4):607–611.
   PubMed Web of Science ®Google Scholar
• Klassen KM, Kimlin MG, Fairley CK, et al. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporos Int. 2016;27(5):1737–1745.
   PubMed Web of Science ®Google Scholar
• Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther. 2014;19(2):191–200.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791–1801.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–972.
   PubMed Web of Science ®Google Scholar
• Cervero M, Agud JL, Torres R, et al. Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy. HIV Med. 2013; 14(9):556–562.
   PubMed Web of Science ®Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab.
   Web of Science ®Google Scholar
• Pludowski P, Karczmarewicz E, Bayer M, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe – recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol. Pol. 2013;64(4):319–327.
   PubMed Web of Science ®Google Scholar
• Avenell A, Mak JCS, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. The Cochrane Collaboration. 2016 Published by JohnWiley & Sons, Ltd Cochrane Database Syst. Rev. 2009, CD000227. doi:10.1002/14651858.
   Google Scholar
• Grant WB, Wimalawansa SJ, Holick MF, et al. Emphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilities. Nutrients 2015;7(3):1538–1564.
   PubMed Web of Science ®Google Scholar
• Silk LN, Greene DA and Baker MK. The effect of calcium or calcium and vitamin d supplementation on bone mineral density in healthy males: a systematic review and meta-analysis. Int J Sport Nutr Exerc Metab. 2015;25(5):510–524
   PubMed Web of Science ®Google Scholar
• Tai V, Leung W, Grey A, et al. Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ 2015;351:h4183.
   PubMed Web of Science ®Google Scholar
• Overton ET, Chan ES, Brown TT, et al. High-dose vitamin D and calcium attenuates bone loss with antiretroviral therapy initiation. Ann Intern Intern Med. 2015;162(12):815–824.
   PubMed Web of Science ®Google Scholar
• Reid Ian R. Osteoporosis treatment: focus on safety. European Journal of Internal Medicine 2013: 24(8):691–697.
   PubMed Web of Science ®Google Scholar
• Ross AC, Taylor CL, Yaktine AL, et al. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press (US); 2011.
   Google Scholar
• Kanis JA. On behalf of the World Health Organization Scientific Group. Technical report. Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases. 2007 Assessment of osteoporosis at the primary helalth-care level. Printed by the University of Sheffield.
   Google Scholar
• Hans DH, Downs RWJ, Duboeuf F, et al. Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9(1):15–21.
   PubMed Web of Science ®Google Scholar
• Eckard AR, O’Riordan MA, Rosebush JC et al. Effects of vitamin D supplementation on bone mineral density and bone markers in HIV-infected youth. Acquir Immune Defic Syndr. 2017;15;76(5).
   Google Scholar
• Lerma-Chippirraz E, Güerri-Fernández R, et al. Validation protocol of vitamin D supplementation in patients with HIV-infection. European AIDS Clinical Society EACS Guidelines AIDS Res Treat. 2016; Hindawi Publishing Corporation AIDS Research and Treatment. Vol 2016
   Google Scholar
• Havens PL, Mulligan K, Hazra R, et al. Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab. 2012;97:4004–4013.
   PubMed Web of Science ®Google Scholar
• Arpadi SM, McMahon DJ, Abrams EJ, et al. Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr. 2012;95:678–685.
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Dawson-Hughes B, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. Br Med J (Clinical research ed).2009:339b3692.
   Google Scholar
• Ross AC, Manson JE, Abrams SA, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 2011;96 (1): 53–58.
   PubMed Web of Science ®Google Scholar
• Grant A M, Avenell A, Campbell M K, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebocontrolled trial. Lancet .2005:365:162–168.
   Web of Science ®Google Scholar
• Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17(13):1917–1923.
   PubMed Web of Science ®Google Scholar
• Carr A, Grund B, Neuhaus J, et al. Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(Suppl 1):137–146.
   PubMed Web of Science ®Google Scholar
• Piso RJ, Rothen M, Rothen JP, et al. Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients. BMC Infect Dis. 2013;13:577. doi10.1186/1471-2334-13-577.
   PubMed Web of Science ®Google Scholar